These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Calculated decisions: DigiFab® (Digibind®) Dosing for Digoxin Poisoning. Lucyk S Emerg Med Pract; 2020 Sep; 22(Suppl 9):CD1-CD3. PubMed ID: 33476509 [TBL] [Abstract][Full Text] [Related]
9. Treatment of digitalis intoxication with emphasis on the clinical use of digoxin immune Fab. Allen NM; Dunham GD DICP; 1990 Oct; 24(10):991-8. PubMed ID: 2244414 [TBL] [Abstract][Full Text] [Related]
10. [Digitalis poisoning in children. Treatment with anti-digoxin Fab antibody fragments. Apropos of a case and a discussion of therapeutic indications]. Jouk PS; Danel V; Bovier-Lapierre M; Frappat P; Barret L; Rossignol AM; Bost M Pediatrie; 1986; 41(3):237-42. PubMed ID: 3774436 [TBL] [Abstract][Full Text] [Related]
11. Review of clinical experience with digoxin immune Fab (ovine). Smith TW Am J Emerg Med; 1991 Mar; 9(2 Suppl 1):1-6; discussion 33-4. PubMed ID: 1997014 [TBL] [Abstract][Full Text] [Related]
12. [The monitoring of plasma digoxin levels during acute digitalis poisoning treated with Fab anti-digoxin fragments]. Milani L; Bizzaro N; Sanson A G Ital Cardiol; 1992 Jan; 22(1):97-101. PubMed ID: 1624074 [TBL] [Abstract][Full Text] [Related]
13. The use of digoxin-specific Fab fragments for severe digitalis intoxication in children. Woolf AD; Wenger T; Smith TW; Lovejoy FH N Engl J Med; 1992 Jun; 326(26):1739-44. PubMed ID: 1594015 [TBL] [Abstract][Full Text] [Related]
14. Digoxin toxicity treated with Digibind. Schakenbach L; Arft P Crit Care Nurse; 1989 May; 9(5):16-22. PubMed ID: 2805742 [No Abstract] [Full Text] [Related]
15. Assessment of digoxin antibody use in patients with elevated serum digoxin following chronic or acute exposure. Lapostolle F; Borron SW; Verdier C; Arnaud F; Couvreur J; Mégarbane B; Baud F; Adnet F Intensive Care Med; 2008 Aug; 34(8):1448-53. PubMed ID: 18389220 [TBL] [Abstract][Full Text] [Related]
16. Monitoring serum digoxin concentrations during digoxin immune Fab therapy. Ujhelyi MR; Colucci RD; Cummings DM; Green PJ; Robert S; Vlasses PH; Zarowitz BJ DICP; 1991 Oct; 25(10):1047-9. PubMed ID: 1803787 [TBL] [Abstract][Full Text] [Related]
17. Immediate control of life-threatening digoxin intoxication in a child by use of digoxin-specific antibody fragments (Fab). Husby P; Farstad M; Brock-Utne JG; Koller ME; Segadal L; Lund T; Ohm OJ Paediatr Anaesth; 2003 Jul; 13(6):541-9. PubMed ID: 12846714 [TBL] [Abstract][Full Text] [Related]
18. Fab antibody fragments: some applications in clinical toxicology. Flanagan RJ; Jones AL Drug Saf; 2004; 27(14):1115-33. PubMed ID: 15554746 [TBL] [Abstract][Full Text] [Related]
19. [Treatment of life-threatening digitalis intoxication with digoxin-specific Fab antibody]. Sato S Kokyu To Junkan; 1989 Oct; 37(10):1055-60. PubMed ID: 2595117 [No Abstract] [Full Text] [Related]
20. Cost-effectiveness analysis of the use of digoxin immune Fab (ovine) for treatment of digoxin toxicity. Mauskopf JA; Wenger TL Am J Cardiol; 1991 Dec; 68(17):1709-14. PubMed ID: 1746476 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]